A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Every 21 Days in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

Inclusion Criteria: * Patient has hormone-refractory prostate cancer (HRPC) as evidenced by PSA progression or progression of measurable disease. * Patient has greater than 25% increase in 2 consecutive tests in which the first increase in PSA should occur a minimum of 1 week apart. * Patients on androgen deprivation treatment and will continue on androgen deprivation treatment during study participation except for patients who are post orchiectomy. * Patient has evidence of metastatic disease by positive bone scan or evidence of progressive metastatic disease by CT scan. * Patient has been treated with at least 1 prior hormone therapy or is post orchiectomy. * Patient has been previously treated at a minimum for an 8-week treatment period on a docetaxel-based regimen for metastatic HRPC. * Patient has PSA at least 5 ng/mL or greater. * Patient has testosterone less than 50 ng/dL. * Patient ECOG performance status of 0 or 1. * Patient has life expectancy of greater than 8 weeks. * Patient meets lab values: A. Absolute neutrophil count at least 1,500/mm\^3 or greater; B.Platelet count at least 100,000/mm\^3 or greater; C. Serum creatinine at least 1.5 mg/dL or less or creatinine clearance at least 60 mL/min or greater; D. Bilirubin less than 2.0 mg/dL. E. AST and ALT less or equal to 2.5 times upper limit of normal * Any chemotherapy, major surgery, or irradiation must be completed at least 4 weeks prior to study drug. * Patient recovered from clinically significant toxicities from prior treatment. Exclusion Criteria: * Prior treatment with 2 or more prior chemotherapy regimens. * Concurrent treatment with an estrogen-containing agent including diethylstilbestrol (DES). * Prior flutamide (Eulexin) within past 4 weeks, prior bicalutamide (Casodex) within past 6 weeks, or prior nilutamide (Nilandron) within past 6 weeks. * Prior strontium or samarium or other radioisotope therapy. * Prior radiation therapy to greater than 25% of the bone marrow (e.g., no whole pelvic irradiation is allowed). * Uncontrolled congestive heart failure or angina, patients with a history of myocardial infarction within 2 months of enrollment. * Patients with uncontrolled hypertension. * Pre-existing cardiac, pulmonary, neurologic or other disease that would preclude study participation. * Documented untreated central nervous system (CNS) metastases. However, patients with treated CNS metastases that have been stable are eligible. * Any significant concurrent disease or illness, or psychiatric disorders or alcohol or chemical abuse that would preclude study participation. * Active secondary malignancy except non-melanoma skin cancers. * Known, active infection, or known HIV positive or presence of an AIDS related illness.